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RNA-Sequencing data offers an opportunity to enable precision medicine, but most
methods rely on gene expression alone. To date, no methodology exists to identify
and interpret alternative splicing patterns within pathways for an individual patient.
This study develops methodology and conducts computational experiments to test
the hypothesis that pathway aggregation of subject-specific alternatively spliced genes
(ASGs) can inform upon disease mechanisms and predict survival. We propose the
N-of-1-pathways Alternatively Spliced (N1PAS) method that takes an individual patient’s
paired-sample RNA-Seq isoform expression data (e.g., tumor vs. non-tumor, before-
treatment vs. during-therapy) and pathway annotations as inputs. N1PAS quantifies the
degree of alternative splicing via Hellinger distances followed by two-stage clustering
to determine pathway enrichment. We provide a clinically relevant “odds ratio” along
with statistical significance to quantify pathway enrichment. We validate our method in
clinical samples and find that our method selects relevant pathways (p < 0.05 in 4/6
data sets). Extensive Monte Carlo studies show N1PAS powerfully detects pathway
enrichment of ASGs while adequately controlling false discovery rates. Importantly,
our studies also unveil highly heterogeneous single-subject alternative splicing patterns
that cohort-based approaches overlook. Finally, we apply our patient-specific results
to predict cancer survival (FDR < 20%) while providing diagnostics in pursuit of
translating transcriptome data into clinically actionable information. Software available
at https://github.com/grizant/n1pas/tree/master.
Keywords: RNA-Seq, precision medicine, isoform, alternative splicing, systems biology, pathways, local false
discovery rate, Hellinger distance
INTRODUCTION
RNA-Sequencing (RNA-Seq) data offers an opportunity to enable precision medicine, but most
methods rely on gene expression alone (Sørlie et al., 2001; Weigelt et al., 2005; Peppercorn et al.,
2008; Bastien et al., 2012; Prat et al., 2014). RNA-Seq, however, provides even greater resolution,
including messenger RNA (mRNA) diversity for the same protein-coding genomic region –
corresponding to distinct protein isoforms, created by alternative splicing of exons. Most RNA-Seq
analytics ignore alternative splicing patterns despite recent evidence that alternative splicing
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is implicated in nearly a third of common diseases. In cancer,
a tumor often displays dysregulation of the cellular machinery
that controls alternative splicing (Yoshida et al., 2011; Kaida
et al., 2012; Ladomery, 2013; Forootan et al., 2016). Yet,
the clinical interpretation of alternative splicing patterns lies
largely unexplored.
This study develops methodology and conducts computa-
tional experiments to test the hypothesis that pathway
aggregation of subject-specific alternatively spliced genes
(ASGs) can inform upon disease mechanisms and predict
survival, thereby providing clinical interpretation of alternative
splicing patterns. By “alternative splicing” patterns, we mean that
the distribution of isoforms of a certain gene differs between two
samples. Specifically, in the context of cancer, our hypothesis
is driven by the high likelihood that comparing non-cancer
(“normal”) tissue to cancer tissue will unveil cell-type specific
expression in cell-type specific pathways. This, in turn, will
affect the proportion of the ASGs in the overall comparison
between tissues (where the cell-type elements have changed)
and will distribute in pathways. Two facts taken together form
this opinion: (1) cellular-specific splicing occurs and (2) if a
differentially expressed gene (DEG) occurs between paired
samples, it is in part due to the change in activated pathways
within the concordant cell types that have become cancerous,
and in part due to the change of cell-type proportions in the
cancer tissue vs. normal tissue (e.g., the stroma may contain
more immune cells that were previously absent).
We and others have recently developed methodological
frameworks to clinically interpret individualized signals from
molecular data (Chen et al., 2012; Yang et al., 2012; Ahn et al.,
2014). In particular, we introduced a statistical framework, N-of-
1-pathways, to provide subject-specific interpretations of the
transcriptome (Gardeux et al., 2014; Li et al., 2017a,b, Schissler
et al., 2015, 2018). The methodology focuses on quantifying
an individual’s dynamic transcriptional response within cellular
pathways, along with providing uncertainty quantification for
these metrics. To this end, paired samples (e.g., normal/tumor,
before, and after treatment) are obtained from a patient, and gene
set analysis (Subramanian et al., 2005; Goeman and Bühlmann,
2007; Khatri et al., 2012) is conducted for the individual without
the requirement of large cohorts.
In this study, we propose a novel methodology to improve
the clinical interpretation of subject-specific alternative splicing
patterns derived from paired RNA-Seq samples. The N-of-
1-pathways Alternatively Spliced (N1PAS) method transforms
a patient’s paired-sample RNA-Seq isoform expression data
(e.g., tumor vs. non-tumor, before-treatment vs. during-
therapy) into a pathway enrichment profile of ASGs. N1PAS
quantifies the degree of alternative splicing using gene-
wise Hellinger distances followed by two-stage clustering
to determine pathway enrichment using a robust, existing
procedure testing procedure – local false discovery rate (locFDR).
The single-subject output provides an interpretable odds ratios
describing the overrepresentation of ASGs along with uncertainty
quantification through locFDR.
The article continues with some brief mathematical back-
ground and description of the proposed method. Then, several
computational experiments explore and validate our proposed
methods in clinical samples. In this proof of concept study, we
demonstrate the potential for alternative splicing interpretation
as one of the Omics signals which should be considered for
predicting cancer survival. We also compare the proposed
method with alternative approaches. Finally, we conduct
extensive simulation studies to explore empirical operating
characteristics of N1PAS. A discussion concludes the article.
MATHEMATICAL BACKGROUND
This section motivates the use of and describes two mathematical
concepts employed in the proposed method.
Hellinger Distance
Our method quantifies alternating splicing between a pair of
samples using the Hellinger distance. Such an approach has
been shown to be useful in the quantification of alternative
splicing in the context of clustering (Johnson and Purdom,
2017). Let the estimates of isoform (mRNA) expression for
sample A be denoted as xgA1, . . . , xgAKg , for the Kg distinct
isoforms annotated to gene g. We define the relative isoform
usage as the vector of relative proportions of each isoform, pgA =(
xgA1∑Kg
k=1 xgAk






k=1xgAk is the total gene
expression (summed over all isoforms) for gene g. The Hellinger
distance between two proportions derived from samples A and B















Simply stated, the Hellinger distance quantifies dissimilarity
between the two distributions of proportions. The result is
a real number Hg that resides in the unit interval, with 0
indicating perfect agreement in isoform usage and values tending
to 1 indicating an increasing difference in relative isoform
distribution of the two samples. Notably, a DEG can also
been alternatively spliced by still displaying a large Hellinger
distance. Also, the Hellinger distance is symmetric (Equation 1)
by definition. To establish a convention, if a gene is not
expressed in both samples, we choose to record a missing value
for the distance.
Local False Discovery Rates
Through Mixture Modeling
Efron’s local false discovery rates provides a flexible and
robust tool for multiple hypothesis testing under correlated
test statistics or effect sizes (Efron, 2004, 2007, 2013). RNA-seq
data quantifying gene and isoform expression are correlated,
both due to the nature of the counting process and biological
considerations. Most statistics (including p-values) derived from
these measurements will also be correlated. So, we need a model
that either specifically accounts for this co-expression or does
not assume independence. Efron discusses the statistical issues in
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detail in Efron (2007), including the close relationship of locFDR
to other false discovery rates, such as Benjamini–Hochberg
(Benjamini and Hochberg, 1995).
Local FDR results from modeling test statistics as arising from
a two-component mixture density. Formally, let zi be an observed
test statistic from i = 1,. . ., N testing procedures. N must be large
to ensure quality locFDR estimates, say at least in the hundreds.
But the zi need not be independent. We assume that the N-values
can be sorted into two classes (“null” and “non-null”), occurring










, f1 (z) density otherwise
.
Define the null subdensity as:
f+0 (z) = p0f0 (z)
And the mixture density:
f (z) = p0f0 (z)+ p1f1 (z)
Then, define the local false discovery rate (locFDR; Equation 2)
as the Bayes posterior probability that a case is null given z:
fdr (z) = Pr {null|z} = p0f0 (z)
f (z)
= f+0 (z) /f (z) (2)
The definition provides a straightforward interpretation: It is the
probability an observed value came from the null density. In
practice, Efron indicates that a locFDR < 0.2 provides strong
statistical evidence that the case is from the non-null distribution.
Methodology: N-of-1-Pathways
Alternatively Spliced (N1PAS)
Here, we describe our proposed method, N1PAS. The approach
aims to transform a single subject’s paired transcriptome data
into an interpretable, mechanism-based profile of alternatively
splicing patterns (Figure 1). We begin by computing a Hellinger
distance for each gene (Equation 1) to quantify differential
isoform usage between the paired samples (Figure 1A). Once
isoform data are transformed into gene-level distances, we
then classify genes as either alternatively spliced vs. not using
conventional 2-means (as in k-means) clustering (Figure 1B).
Next, we quantify an enrichment of ASGs within a gene set
(pathway). That is, odds ratios (OR; Equation 3; Figure 1C)
compare the relative abundance of ASGs within the pathway vs.
the genes not in the pathway:
ORpathway
=
# of ASGs in pathway/# of non-ASGs in pathway
# of ASGs not in pathway/# of non-ASGs not in pathway
(3)
Then, we calculate locFDR values (Equation 2) by fitting the two-
component mixture model to the distribution of pathway odd
ratios (Figure 1D). This whole process results in a single-subject,
mechanistic profile of alternative splicing, along with effect size
and statistical significance (Figure 1E).
METHODS FOR COMPUTATIONAL
EXPERIMENTS
This section describes computational experiments to explore,
validate, and apply N1PAS. We conduct these studies using RNA-
Seq data derived from clinical samples housed in The Cancer
Genome Atlas (TCGA). Pathway annotations are based on the
Kyoto Encyclopedia Genes and Genomes (KEGG; Kanehisa and
Goto, 2000). Survival data were also retrieved from the TCGA.
Data Set Acquisition, Preprocessing,
Pathway Ontology
Data sets were selected based on the availability of: (1) paired
normal-tumor isoform-level quantification from each cancer
patient, (2) a KEGG pathway annotated to the same cancer, and
(3) survival data. Six TCGA data sets were identified (Table 1)
meeting that criteria. The Broad GDAC Firehose was employed to
retrieve RNA-Seq data in the form of RSEM normalized isoform
expression (downloaded 25/7/2017)1. The UCSC Table Browser
(Goldman et al., 2015) was used to map isoform identifiers to the
corresponding HGNC host gene symbol. In total, 73,599 isoform
measurements were associated with 29,181 unique gene symbols.
Since for many genes, it is non-trivial to estimate isoform levels
correctly due to ambiguity in assigning reads, we used the RSEM
adjusted expression values.
The RNA-Seq data sets were filtered to include patients with
paired normal-tumor data. Such patients were identified via
the R library TCGA2STAT (Wan et al., 2015). Further, clinical
information including survival data for the subjects was queried
using this library. The data were normalized using transcripts
per million (TPM) to make library size adjusted comparisons
between samples derived from the same patient.
Genes were annotated to KEGG gene sets (pathways) using the
Bioconductor database KEGG.db version 2.3.5, downloaded 16
Sep 2009. In total, 230 gene sets were downloaded. To improve
efficiency of the algorithms developed, the 73,599 isoforms
measured were filtered to only those that mapped to a gene
annotated to a KEGG pathway (5,879 unique genes), resulting
in 18,823 isoform-level quantities for the 5,757 genes measured
in the TCGA data set. Following standard practice in alternative
splicing analytics (Johnson and Purdom, 2017) only genes with
at least 2 and no more than 30 isoforms were retained, leaving
17,088 isoform measurements on 4,133 genes. Lastly, in order to
maintain interpretability and stability, the pathways were filtered
to have at least 15 and no more than 500 genes – resulting in 206
pathways considered.
KEGG Target Pathway Validation Study
We aim to validate our methods by exploring N1PAS results
within KEGG target pathways. Our strategy here was inspired
by the work of Diaz et al. (2017). Similar to Diaz et al. (2017),
1http://gdac.broadinstitute.org/
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FIGURE 1 | Workflow of N1PAS. (A) Isoform-specific mRNA-Seq data are obtained from an individual. Gene-level distances between the two samples indicates the
magnitude of alternative splicing. (B) Gene-level distances are aggregated across the whole transcriptome and unsupervised clustering classifies genes as
alternatively spliced genes (ASGs; blue) and not (red). The vertical axis shows the count of genes with Hellinger distances binned together to form the histogram.
Note that since this is a univariate setting, 2-means simply finds a threshold Hellinger distance to classify the genes into two groups. Gene set (pathway) enrichment
analysis is conducted by first (C) computing the odds ratio (OR) to quantify the relative abundance of ASGs in the pathway vs. genes not in the pathway
(background). ORs are calculated for each pathway in the data-base to produce an empirical, subject-specific distribution (D). A local false discovery procedure
provides uncertainty quantification (FDR) and classified pathways as enriched using a simple threshold at FDR < 20%. (E) Results are tabulated to provide an
individualized profile of alternative spliced enrichment.
TABLE 1 | Characteristics from six TCGA RNA-Seq data sets with paired normal-tumor data, survival data, and associated target KEGG pathway.
Target KEGG Number of Number Isoforms
TCGA Cancer pathway description patients deceased measured
LUSC Lung squamous cell carcinoma Non-small cell lung cancer 51 32 73,599
LUAD Lung adenocarcinoma Non-small cell lung cancer 58 26 73,599
PRAD Prostate adenocarcinoma Prostate cancer 52 0 73,599
THCA Thyroid carcinoma Thyroid cancer 59 4 73,599
UCEC Uterine corpus endometrioid carcinoma Endometrial cancer 7 2 73,599
BLCA Bladder carcinoma Bladder cancer 19 11 73,599
we define a target pathway as a KEGG pathway whose description
matches the disease associated with the RNA-Seq data set (see
Table 1). The validation study will use descriptive statistics
and empirical (permutation-based) significance assessments to
determine to what extent target pathways were identified
as enriched. Differing from Diaz et al. (2017), the analysis
is conducted for each individual patient, and, thus patient
heterogeneity within target pathways will also be studied.
Moreover, we broaden the concept of target pathways to
cancer pathways, as defined by any KEGG pathway with cancer
contained in the description. In total, there are nine cancer
pathways, five target pathways listed in Table 1 and four
additional KEGG pathways, described as pathways in cancer,
small cell lung cancer, pancreatic cancer, and colorectal cancer. To
form descriptive statistics, a pathway capture rate is defined as
the proportion of patients that found the pathway significantly
enriched at locFDR < 20% and odds ratio > 1. In the case of
cancer pathways, a cancer pathway capture rate is the proportion
of patients that found at least one of the cancer pathways
enriched. Note that N1PAS was carried out using all 206 KEGG
pathways and the detection rate of target and cancer pathways
was explored to validate our methodology.
The above-mentioned empirical significance assessment
entails producing 2000 null binary matrices of size N (patients)×
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P (pathways). The assessment begins with the original matrix of
alternatively splicing calls – 1 indicating that a pathway had both
an odds ratio greater than 1 and locFDR was less than 0.20, and
0 otherwise. Then each patient’s values (rows) are shuﬄed. This
procedure will preserve the number of 0’s and 1’s within each
patient while disrupting the correspondence across individuals
and pathways. Thus, each column forms a synthetic null pathway
with values not tied to any particular pathway annotation
while preserving the patient distributional characteristics. Once
shuﬄed, a null pathway is randomly selected and the number
of 1’s (significant pathways) are counted to calculate the null
capture rate. The procedure is repeated 2000 times to form an
approximate null distribution for the capture rate for a single
pathway. An empirical p-value is the proportion of null pathways
with a higher capture rate than the observed target capture
rate for a given data set. To assess the capture rate for at least
one of nine selected pathways (mimicking the cancer-annotated
capture rate), the capture rate of at least one of nine pathways
is computed by selecting nine columns at random, without
replacement, and counting a “success” as at least one “1” in the
vector of 9 values. This procedure is repeated 2000 to produce
a null distribution corresponding to the chance of capturing at
least 1 out of 9 cancer-annotated pathways. The empirical p-value
for this assessment is proportion of times the null capture rate
is larger than the observed cancer capture rate. The assessment
is limited as it makes no adjustment for the fact that smaller
pathways correspond to more variable odds ratios (and therefore
different probabilities of alternative splicing calls).
There are caveats to using local FDR for testing pathways in
the KEGG database. The locFDR implementation in R (locfdr)
contains default parameters that assume there are a large number
of tests (at least 1000). Since there are approximately 200
pathways under consideration, custom configurations needed to
be developed. Based on practical experience with the pathway
odds ratio distributions, the model fits reasonably well using the
following heuristic procedures: (1) filter outlier odds ratios and
set FDRloc to 0 for those pathways, (2) the number of breaks
in the histogram is set to 25, (3) nulltype is set to “Central
Matching” to provide less conservative results (to compensate
for small sample issues), and (4) the mixture density estimate’s
degrees of freedom is set to 4. In larger ontologies, program
defaults should be adequate, but the model fit should always be
inspected. It is important to note that the number of genes in
each pathway does not play into any locFDR calculations. We
chose to forgo any formal inferences at the gene level as it is rate
prohibitive to manually inspect and adjust the fit at the first stage
of clustering (Figure 1B). Instead, we employ a 2-means strategy
to classify genes as ASGs.
Disease Subtyping Pipeline Using N1PAS
Single-Subject Metrics
We now describe a pipeline to produce disease survival subtypes
from the output of our proposed method (Figure 2). The three
pipeline inputs include: (i) paired-sample isoform measurements,
(ii) a database of pathway annotations, and (iii) survival data.
First, odds ratios and locFDR values are calculated using N1PAS
(see Figure 2A) for the N patients in the data set (Table 1).
Next, the odds ratios across all P pathways in the database
are aggregated into an N × P matrix (Figure 2B). To reduce
noise from non-informative pathway signal, the pathways are
filtered to only pathways in which at least one patient is
significantly enriched with ASGs (FDRloc < 20%). This produces
a new odds-ratio matrix (Figure 2C) with P′pathways (P minus
the number of filtered pathways). Now, patients are clustered
(unsupervised) into two groups (for simplicity and potential
clinical utility) using only the odds ratios for a single pathway
(Figure 2D). To this end, we used partitioning around medoids,
a robust version of k-means with the number of groups a priori
set to two. For each clustering (one per pathway), Kaplain–
Meier estimates (Klein and Moeschberger, 1997) of the survival
curves are computed (Figure 2E). A log-rank p-value assesses
whether these two curves are distinct. Moreover, we devise
the construction of an empirical null distribution of log-rank
p-values for a pathway (Figure 2F). This procedure is similar to
the empirical p-value approach above. We begin with shuﬄing
patient’s odds ratios across the P′pathways. Thus, this forms a
synthetic null pathway with values not tied to any particular
pathway annotation while preserving the patient distributional
characteristics. The patients were then clustered using these
null values, and survival log-rank p-values were computed. This
process was repeated 2000 times to produce an empirical null
distribution of odds ratios. The observed log-rank p-value for
each pathway is compared to this null distribution (red line
in Figure 2F). This results in an empirical p-value for every
pathway under consideration. Then the empirical p-values are
adjusted using a Benjamini–Hochberg FDR adjustment (FDRBH).
Pathways withFDRBH < 20% are identified as survival-relevant
pathways (Figure 2G). Clusters resulting using the N1PAS
metrics within relevant pathways provide disease subtypes with
distinct survival curves (Figure 2H) with the added benefit of
simple diagnostic tools – relevant pathway odds ratio thresholds
as depicted in Figure 2I.
Alternative Approaches to
Survival Subtyping
To explore whether pairing and aggregating alternative
spliced genes at the pathway level improves the detection of
survival-relevant pathways, we modify the above pipeline by
systematically modifying the input to the binary clustering
in three ways: (1) use only the tumor isoform expression
(as opposed to N1PAS odds ratios and locFDR), (2) use the
difference in tumor isoform expression from the normal isoform
expression, and (3) use the Hellinger distances corresponding to
each of the 4133 KEGG-associated genes The first method differs
from N1PAS in that for each pathway W with IW associated
isoforms (all isoforms relating to the G genes annotated W),
all IW isoform measurements are included in the call to the
PAM clustering algorithm. The second method uses both the
tumor and normal isoform expression, but is only concerned
with differential expression not alternative splicing patterns.
The third method quantifies differential isoform usage, but
does not aggregate these patterns at the pathway level (as in
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FIGURE 2 | Workflow of the disease-subtyping pipeline. Single-subject N1PAS pathway-level metrics (A) are aggregated for the patients in the cohort (B). Then, the
dimension is reduced by filtering out pathways that are not significantly enriched in any patient (C). For each prioritized pathway remaining, patients are clustered
(unsupervised) into two subtypes (D). Two Kaplan-Meier survival curve estimates are produced along with a log-rank p-value (E). An empirical distribution of p-values
is computed to assess significance (F). The top-prioritized pathways are called survival relevant pathways (G). (H) displays the survival curves for patient clusters
derived in relevant pathways. The curves presented here depict the results from a clustering that passed the empirical p-value threshold from (E). There is no
difference in the clustering approach – just an illustration of a successfully identified survival-relevant pathway. Lastly, decision-friendly cutoffs are provided to inform
at the point of care (I).
N1PAS). As we defined the Hellinger distance only when
both samples expressed the gene, care was needed to form a
complete 51 × 4133 matrix of Hellinger distances. Specifically,
any missing gene-wise distances were imputed with a patient’s
mean Hellinger distance across all genes. Each method produces
two patient clusters as in Figure 2D and survival curves are fit
for each of the 206 pathways. To construct an empirical null
of survival p-values, each patient’s IW isoforms or genes were
shuﬄed to disrupt correspondence with the specified pathway’s
true annotations (similar to the other permutated distributions
above) and two clusters are determined. Relevant pathways
are identified using the FDR-corrected empirical p-values as
shown in Figure 2G.
Simulation Study of N1PAS Empirical
Operating Characteristics
To investigate the performance of our N1PAS methodology in
practice, we conducted a series of Monte Carlo evaluations. We
examined how two different inputs affect the test’s operating
characteristics: (1) number of expressed genes, G, in the
pathway and (2) proportion, pi, of ASGs within the pathway
over the background percentage of ASGs. We study the
empirical false positive rates and (statistical) power to detect
an enriched pathway based on permutations of patient-specific
Hellinger distances for all 246 TCGA patients (Table 1) while
varying the two above inputs. Our focus lies in providing
practitioners guidance to calibrate what effect size N1PAS
can reliably detect. The pathway odds ratio serves as an
effect size in N1PAS. This effect size corresponds to the
proportion of ASGs within a pathway (pi), relative to the
background level of ASGs. We explain the details of the
simulation below.
To avoid over-simplistic parametric and statistical assump-
tions (e.g., independent isoform counts) and to anchor
simulation results to our studied setting, we restricted our
Monte Carlo experiments to permutated TCGA patient-specific
Hellinger distances for genes annotated to KEGG pathways.
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First, Hellinger distances within each gene were computed for
all 246 patients across the 6 TCGA data sets. This produces
patient-specific distributions of distances that are then used to
classify genes into two groups: ASG or not (as in Figure 1B)
for each patient. The proportion of ASGs across all genes is
what we refer to as the patient-specific background level and
denote this quantity aspiall. Next, for each patient, we shuﬄe
the gene labels to approximate a ‘null’ distribution of Hellinger
distances as the values do not aggregate meaningfully into
pathways. Then the number of expressed genes G (approximate
gene set size) is selected from the set {15, 30, 50, 100} and
an effect size pi is selected from the set {0, 0.05, 0.10, 0.15,
0.20}. Next, we randomly select one of the 206 KEGG pathways
that has at least G expressed genes (but not more than 5
genes larger than the G, to give an approximate gene set
size) to label Hellinger distances with specific gene labels to
induce the effect size pi. Call this selected pathway the specified
pathway. To induce the specified effect size, G∗(pi+ piall) gene
labels within the specified pathway were randomly chosen and
assigned randomly sampled Hellinger distances from the ASG
group. The remaining genes were randomly assigned values from
the non-ASG group. Then N1PAS was run on the permuted,
modified Hellinger distance data for all 206 KEGG pathways.
This process was completed 100 times across the 4× 5 simulation
configurations for a total of 2000 runs per patient. This results
in 246 patients × 2000 runs per patient for a total of 492,000
simulated N1PAS runs.
RESULTS
This section describes observations from the target KEGG
pathway validation study across six TCGA data sets (Table 1),
an application of the disease-subtyping pipeline to the
TCGA LUSC data set of 51 lung squamous cell carcinoma
patients, and the Monte Carlo studies. Throughout, we
focus on the interpretation of single-subject results to
showcase the unique insights made possible by N1PAS.
Overall, the results highlight the vast heterogeneity of
splicing dysregulation among cancer patients, despite having
the same disease.
Target KEGG Pathway Validation Study
The frequency of significantly enriched pathways of ASGs
varies greatly from data set to data set and patient to patient.
Table 2 compiles the results of the KEGG target pathway
validation study. We only scored pathways with at least 15
expressed genes (in either sample from a patient). Of the
206 KEGG, the number of pathways scored across all data
sets was fairly constant (with a median of approximately
185 pathways). The locFDR significance threshold appears
somewhat severe with the median percent significantly enriched
ranging from 3 to 7.8% across data sets. So, it is quite
difficult in this small ontology to call a pathway as enriched
with ASGs. One should keep in mind that pathway can
have a high proportion of ASGs yet still not be significantly
enriched, especially if alternative splicing is rampant through the
entire transcriptome.
The target pathway capture rate (i.e., the proportion of
patients with a significantly enriched target pathway) is greater
than expected for most data sets. The KEGG pathway bladder
cancer was the most often-captured target pathway, with 9 of the
19 (47%) Bladder Cancer (BLCA) patients significantly enriched.
To put this in context, a random null pathway for the BLCA
data was never captured at such a high rate in 2000 empirically-
derived pathways (Table 2; p < 0.001). In fact, the target capture
rate is greater than expected for all data sets except for the two
lung cancer data sets (LUSC and LUAD). Moreover, the rate of
cancer pathway capture is higher than expected from four of
the six data sets.
While the capture rates on the surface appear lukewarm,
we view the results as unveiling the need for subject-
specific metrics. If one relied on cohort-based methods, the
heterogeneity in splicing patterns would be missed. To explore
this notion, we clustered patients into two groups using
the odds ratios within target pathway. Figure 3 illustrates
these grouping across the six data sets. Many patients show
an enrichment of ASGs within patients (OR > 1) while
TABLE 2 | Summary for target capture validation study and empirical assessment.
Target KEGG Median # scored Median # of Target pathway capture Median target Cancer pathway capture
TCGA (N) pathway pathways hit pathways % (p-value) pathway rank % (p-value)
LUSC (51) Non-small cell lung cancer 186 11 4% (ns) 58 47% (p = 0.03)
LUAD (58) Non-small cell lung cancer 183 10 9% (ns) 49 52% (p = 0.001)
PRAD (52) Prostate cancer 185 6 15% (p < 0.001) 28 42% (p < 0.001)
THCA (59) Thyroid cancer 185 9 20% (p < 0.001) 37 39% (ns)
UCEC (7) Endometrial cancer 182 14 9% (p < 0.038) 44 57% (ns)
BLCA (19) Bladder cancer 181 11 47% (p < 0.001) 11 68% (p = 0.004)
206 KEGG pathways were used as the input. There is one target pathway per data set and nine cancer pathways in the KEGG ontology (9/206 = 0.044). A “pathway
capture rate” is the proportion of patients with the target pathway (or set of pathways) found significantly enriched at FDRloc < 20% and odds ratio > 1. A “cancer
pathway capture rate” is the proportion of patients with at least one of the nine cancer pathways that was found to be enriched. The “null pathway” capture is the rate of
a randomly-constructed “pathway” being enriched and, similarly, the null “cancer pathway” is the rate of at least one of nine null pathways found enriched. See section
Methods for Computational Experiments for details. The “median # scored pathways” contains the median of the distribution of the number of scored pathways across
patients (as the pathway must have at least 15 expressed genes, this varies from patient to patient). Similarly, the “median target pathway rank” contains the median rank
across the patients for the corresponding target pathway. ns, not significant.
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FIGURE 3 | Boxplots of patient-specific odds ratios (OR) of the target KEGG pathway for the six TCGA data sets. Patients (indicated by points) were clustered using
only the OR of the target pathway into two groups to unveil transcriptional response subtypes. Note that some patients exhibit less alternatively spliced genes within
the target pathway than the background transcriptome (see LUAD, LUSC, and UCEC data sets; OR < 1).
others do not. Perhaps some patient’s disease mechanisms
are not in a well-studied pathway and could be helped by
innovative strategies.
Applying the Disease-Subtyping Pipeline
to the Non-small Cell Lung Cancer
(LUSC) Data Set
The low target-capture rate (3%) and high cancer pathway
capture rate (47%) for the LUSC data set (Table 3, first row) and
apparent impoverishment of ASGs for some patients (Figure 3)
presents an interesting dilemma. Is the target pathway useful
for these data? Or are there other, more interesting pathways
related to patient outcomes? For this quandary, we applied the
survival-subtyping pipeline to the 51 LUSC paired normal-tumor
isoform expression, using KEGG pathways, and clinical survival
data (32 deaths observed). Following the pipeline workflow
illustrated in Figure 2, the 206 KEGG pathways meeting the
filtering criteria were scored for each of the 51 patients. Next, the
odds ratios were aggregated into an N × P matrix (Figure 2B).
TABLE 3 | Non-small cell lung cancer (LUSC) pathways selected by subtyping pipeline.
Log-rank Empirical p-value % significant % genes shared w/
Rank KEGG description p-value (2000 reps) # genes enrichments target pathway
1 Bladder cancer 0.0001 0.0005 42 18% 52%
2 Melanoma 0.002 0.003 71 24% 47%
3 Staphylococcus aureus infection 0.003 0.004 55 18% 0%
4 Non-small cell lung cancer∗ 0.005 0.007 54 4% 100%
5 Renal cell carcinoma 0.006 0.009 70 18% 36%
Top-five ranked pathways out of 101 KEGG pathways enriched for at least one of the 51 patients (FDR < 20%). Pathways are ranked by log-rank p-value between
survival curves corresponding to clustering of enrichment odds ratios. As shown by the high prioritization of the biologically relevant LUSC target pathway in this table, the
proposed method using ORs of spliced pathways outperforms alternate analytical processing of alternative splicing signal as input to clustering as shown in Table 5. The
columns headings explained: The “log-rank p-value” corresponds to the standard Kaplan-Meier p-value (unadjusted) for the pathway-based clustering. The “empirical
p-value” results from our permutation test. The “# genes” is the number of annotated genes from KEGG. “% significant enrichments” column contains the percentage of
subjects that were identified as having the significant enrichment of ASGs. The “% genes shared w/target pathway” contains the percent of genes annotated to the target
pathway for each top-rank pathway ∗ = Target pathway. Bolded values denote the summary statistics of the LUSC target pathway.
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P is determined by the number of pathways scored in at least
one patient. For these data, there are 174 such pathways. The
pathways were further filtered to reduce noise to include only the
101 pathways found significantly enriched in at least one patient
(Figure 2C). Next, each pathway is assessed one at a time to
determine if unsupervised clustering of patients, based on odds
ratios, into disease subtypes produces distinct survival curves
(Figures 2D–G). Table 3 displays the discovered survival-relevant
pathways (Diaz et al., 2017). Survival curves for the top-four
pathways are provided in Figure 4.
Thus, the N1PAS odds ratios and locFDR values were able
to predict survival in the LUSC data set, as five pathways were
found atFDRBH < 20% (Table 3). Interestingly, four of these
pathways relate to cancer with the fourth-ranked pathway being
the LUSC target pathway. Surprisingly, the third-ranked pathway
is the staphylococcus aureus infection KEGG pathway, which may
present an orthogonal explanation for a poor survival outcome.
Figure 5 displays the odds ratio distribution within the top-
four relevant pathways split by patient clusters (subtypes). Patient
subtypes have been annotated as Better or Worse based on
inspection of the survival curves. For the three cancer-annotated
pathways, a higher odds ratio of enrichment with ASGs is
associated with a better survival outcome. This paradoxical
observation may be the result of drug efficiency directed at known
cancer biology. The reverse pattern lies in the staphylococcus-
related pathway – more abundant alternative splicing in the
pathway results in poor survival. Simple diagnostic rules can be
found by inspection of the boxplots in Figure 5. For example,
a patient-specific odds ratio less than 1 in the non-small cell
lung cancer pathway (target pathway; Figure 5D) indicates a
poorer prognosis.
One practical issue with subtyping a patient using multiple
survival-relevant pathways is that different clusterings may
disagree with prognosis (Better using one pathway’s odd ratios
FIGURE 4 | LUSC patient (N = 51, 32 deaths) survival curves. Subgroups determined by unsupervised clustering into two groups (Better and Worse) using the odds
ratio for the corresponding KEGG pathway. (A) Bladder cancer pathway (NBetter = 28), (B) Melanoma pathway (NBetter = 33), (C) Staphylococcus aureus infection
pathway (NBetter = 21), and (D) Non-small cell lung cancer pathway (NBetter = 33). Circles indicate censorship. All log-rank p < 0.01.
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FIGURE 5 | Boxplots overlaid with points indicating the odds ratios of pathway enriched with ASGs. Points indicate values for the 51 LUSC patients, split by
unsupervised cluster assignment into two groups (“Better” and “Worse” as interpreted by survival data) for pathways (A) “Bladder cancer” (NBetter = 28), (B)
“Melanoma” (NBetter = 33), (C) “Staphylococcus aureus infection” (NBetter = 21), and (D) “Non-small cell lung cancer” (NBetter = 33). Circles indicate censorship.
Since the clustering is done on a single vector of odds ratios for each pathway, an odds ratio threshold can separate the patients (red dashed lines; midpoint
between clusters).
and Worse using another’s). This will require care to uncouple
for the patient at hand. For example, a patient may exhibit a
worse prognosis in the staphylococcus aureus infection pathway,
but a better prognosis in the cancer-annotated pathways.
Hypothetically, this patient may then respond well to the
standard treatment in combination with an innovative treatment
to address the dysregulation in the staphylococcus pathway.
To gain insight into subtype overlap within our LUSC case
study, we explore agreement across the top-four survival-relevant
pathways (Table 3). To quantify the agreement, we compute
the Jaccard index asJ1,2 = |G1∩G2||G1∪G2| , where G1, G2 are the sets
of patients clustered using the 1st and 2nd top pathways (for
either the Better or Worse subtype). Table 4 displays the Jaccard
indices for all pairs of top ranked pathways for both subtypes.
The quantities suggest that agreement is stronger for the Better
subtype (average Jaccard index of 0.4942, compared to the
average Worse index of 0.3255). This is interesting as it may
indicate that individual lung cancer patients display unique
dysregulated pathways (motivating precise treatments). We also
observe that subtyping based on the three cancer-associated
pathways (ranks 1, 2, 4) generally agree well for the Better
patients. But these Better subtypes from cancer pathways agree
poorly with the staphylococcus aureus infection subtyping. The
Worse subtypes generally agree less well than the Better subtypes,
and with a similar trend in disagreement with the staphylococcus
pathway. This suggests a distinct survival-related signal in this
pathway from the cancer-annotated dysregulation. Of course,
conflicting subtypes will complicate clinical application and slow
any decision process, thus limiting our proposed approach.
Comparing Alternative Approaches to
Survival Subtyping
As detailed in section Alternative Approaches to Survival
Subtyping, the input data to the clustering step of our proposed
subtyping pipeline was modified using three straightforward
alternative approaches for the 51 LUSC patients: (1) using tumor
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TABLE 4 | Subtype agreement across the top-four LUSC
survival-relevant pathways.
Subtype J12 J13 J14 J23 J24 J34
Better 0.605 0.289 0.605 0.370 0.784 0.313
Worse 0.464 0.159 0.464 0.147 0.636 0.083
The Jaccard index measures the proportion of overlapping patients selected in
either the Better or Worse group by each pair of top-ranked pathways (Table 3).
The first, second, and fourth pathways are all associated with cancer annotated
genes and their comparisons show highest agreement scores.
isoform expression, (2) using the difference in isoform expression
between tumor and normal samples, and (3) Hellinger distance
data for the 4133 genes annotated to KEGG pathways. Table 5
summaries the pathway rankings and statistical significance of
survival prediction for the three alternative approaches. We’ll
discuss the results of each method in turn.
The tumor-expression method clusters solely on the isoform
expression and uses no dimension reduction techniques prior
to clustering. This could perhaps provide more information in
the cluster assignments. No pathways, however, were found to
be statistically significant at FDR < 50%. But this approach
uses only half of the expression data input into N1PAS; thus, it
may suffer reduced ability to detect survival-relevant pathways
based on that fact alone. The top pathways’ descriptions appear
to be less relevant than the results for N1PAS (Table 3).
The non-small cell lung carcinoma target pathway is ranked
relatively poorly (64 out of 206 pathways, compared to the
fourth-ranked pathway using N1PAS in Table 3). These results
seem to imply that clustering on the dynamic, individualized
metrics of differential isoform usage within pathways provides
higher resolution for survival prediction than tumor isoform
expression alone.
Next, we use the difference in tumor and normal isoform ex-
pression as input to the binary clustering of LUSC patients. The
top-ranked survival-relevant pathway, phenylalanine metabolism,
agrees with the tumor-only results. The other top pathways
disagree, suggesting a distinct signal. The non-small cell lung
carcinoma target pathway’s rank dropped substantially in this
approach to a rank of 144 out of 206 KEGG pathways when
compared to the N1PAS results reported in Table 3. No pathways
were found to significantly produce separate survival curves
at FDR < 50%.
Finally, we use the Hellinger distances for each gene across
the 51 LUSC patients to cluster patients. This signal is somewhat
nearer to N1PAS and is concerned with alternative splicing
patterns. N1PAS takes these distances one step further by
aggregating the signal into pathway-level enrichment of ASGs (by
operating with the odds ratios; Figure 1C). The non-small cell
lung carcinoma target pathway rank is also low (30 out of 206
KEGG pathways) when compared to the N1PAS method reported
in Table 3. The top hit pathway, chronic myeloid leukemia,
TABLE 5 | Complementary study of LUSC survival-relevant pathway rankings by subtyping pipeline using three alternative analytical transformations (first column;
clustering inputs) before clustering.
Log-rank Empirical Empirical
Clustering input Rank KEGG description p-value p-value FDRBH
Tumor isoform expression only 1 Phenylalanine metabolism 0.0017 0.005 0.515
2 Complement and coagulation cascades 0.0024 0.0030 0.515
3 Pentose phosphate pathway 0.0106 0.0245 0.750
4 Vasopressin-regulated water reabsorption 0.0112 0.018 0.750
. . . . . . . . . . . . . . .
64 Non-small cell lung cancer (target pathway) 0.130 0.217 0.750
Difference in tumor and normal isoform
expression
1 Phenylalanine metabolism 0.0014 0.003 0.618
2 RNA degradation 0.0034 0.0140 0.747
3 GnRH signaling pathway 0.0037 0.017 0.747
4 Glycolysis/Gluconeogenesis 0.0130 0.0285 0.747
. . . . . . . . . . . . . . .
144 Non-small cell lung cancer (target pathway) 0.571 0.6025 0.854
Hellinger distance within genes across
isoform expression
1 Chronic myeloid leukemia < 0.001 0.0005 0.103
2 Osteoclast differentiation 0.0035 0.0060 0.618
3 Steroid biosynthesis 0.0111 0.0150 0.762
4 Progesterone-mediated oocyte maturation 0.0130 0.0155 0.762
. . . . . . . . . . . . . . .
30 Non-small cell lung cancer (target pathway) 0.1186 0.136 0.899
In order to demonstrate that the proposed method evaluated in Table 3 outperforms straightforward analytical transformations (first column, clustering inputs), we
conducted these additional substudies (section Methods for Computational Experiments). The non-small cell lung cancer pathways of KEGG is the most relevant to LUSC
survival and is ranked higher (#4, Table 3) in the proposed method than in the alternate ones presented here. Ranked pathways of the 206 KEGG pathways with at least
15 and no more than 500 genes. Empirical p-values are constructed by comparing to survival curves generated from clustering on permutations of the clustering input
data expression. Bolded values denote the rank of the LUSC target pathway.
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FIGURE 6 | Extensive simulations of false-positive rates under the assumption
of locFDR < 20% shows conservative 4–5.25% false-positive rates for the
N1PAS method. Empirical false-positive rates are represented as dots for
each TCGA data set, based on simulated patient-specific Hellinger distance
data. Results reported for pi = 0 (see text). Horizontal bars are 95%
confidence intervals around the overall mean false-positive rate (across
patients within the data set). For example, the confidence interval for LUSC
was constructed by first finding the average patient-specific false-positive rate
for all 51 patients (51 patients × 100 replicates/patient = 5100 simulations for
LUSC). Then, the standard error of the overall mean was estimated using the
sample standard deviation across patients and a normal approximation is
used to determine the confidence bounds.
was significant at FDR < 20% – in contrast to the two other
alternative methods.
Put together, we see that the use of N1PAS odds ratios and
significance assessment increases the ability to find survival-
relevant subtypes within pathways. The results also suggest
that alternative splicing analyses within pathways present a
complementary viewpoint to expression-based workflows.
Simulation Results
Our simulation results provide insight into N1PAS empirical
operating characteristics, specifically simulated false-positive
rates and statistical power. Among the 492,000 N1PAS runs,
there were 625 algorithm failures (0.127%) due to misfit
odds ratio mixture modeling. This may happen in practice,
although rarely, and the parameters of locFDR will have to
be manually adjusted. Here, we discarded these runs from
the results. Each patient displays a different Hellinger distance
distribution with their own background level of ASGs (piall). The
average piall across the 246 patients is 0.1914, but vary from
0.1088 to 0.4417 with the middle 50% of the rates vary from
0.1613 to 0.2122.
Empirical false-positive error rates correspond to the pi = 0
simulation setting (no pathway is specified to have an
enrichment of ASGs). ASGs can aggregate in pathways by
chance in this setting. We calculated the simulated false-
positive rate as the number of detected pathways among the
206 KEGG pathways under permuted patient-specific Hellinger
distances. We performed 100 simulation replicates per patient
and computed the patient-specific average false-positive rates.
Further, we pooled these mean rates within each TCGA data
set and computed the empirical standard error of the mean to
assess variability across patients. Finally, we computed pointwise
95% confidence intervals for the data set mean false-positive rate
using a normal approximation centered at the overall mean with
the observed standard error. Figure 6 displays these mean false-
positive rate estimates. The patient-specific average false-positive
rates vary tightly around 0.04–0.0525 with centers between 0.045
and 0.050. This is interesting since the decision threshold used
in N1PAS was locFDR > 0.20, and we observe rates much lower
than this specification. This trend in false-positive rates persists
across TCGA data sets. In sum, the simulated false-positive rate
data suggests adequate (if not conservative) method performance
with respect to false discovery rates.
Empirical power estimates, as detection rates, from our
simulations are graphed in Figure 7. Power calculations
correspond to simulations withpi > 0. Here we call power the
observed detection rate of a specified pathway, with an induced
enrichment of ASGs. Figure 7 presents the results as a function of
the ASG proportion above background (pi), and stratifies power
curves by expressed genes in pathway (G). We increment the
effect size pi from 0.05 to 0.20 to calibrate how sensitively N1PAS
can detect an enriched pathway. 95% confidence intervals for
mean power were constructed at each pair (pi,G) within each
data set as above in the false-positive rate study.
Patterns in Figure 7 show a trend toward increasing power
while increasing the effect size pi. N1PAS rarely detects a
5% enrichment of ASGs over the background level. At 10%,
however, detection is possible but highly variable. At 15% ASGs
above background, power becomes more reliable with 75%
of average power estimates above 0.9. At 20%, the specified
pathway in almost always detected (minimum patient-specific
power = 0.9916). The trends in simulated power are generally
consistent across TCGA data sets at extreme values of pi, 0 or 0.2.
There are, however, some differences in central tendency and
variability across TCGA data sets atpi = 0.1, 0.15. For example,
PRAD patients show more power to detect a specified pathway
with a 15% ASG enrichment than BLCA. As one may expect,
power estimates are more variable with a smaller number of
expressed genes G for immediate values of pi (e.g., 0.1 or 0.15).
In general, these results suggest that N1PAS procedure exhibits
good false-positive error control and excellent power, at least
under the settings chosen for these simulations.
DISCUSSION
This study creates a first look at personalized alternatively
splicing patterns within pathways. As such, these patterns are
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FIGURE 7 | Extensive simulations show substantial statistical power of N1PAS method in detecting pathways enriched with Alternatively Spliced Genes (ASGs)
when the specified pathway’s proportion (pi) is 15% higher than subject-specific background level of ASGs (piall ). Approximately 400,000 simulations were conducted
to assess power by varying expressed genes in the specified pathway (G), proportions pi, and gene labels assignment for patient-specific Hellinger distances.
Empirical power estimates are displayed as jittered dots for each TCGA data set, based on the detection rate of a specified pathway. Horizontal bars are 95%
confidence intervals around the overall mean power (across patients within the data set, stratified by G and pi). Power curves were constructed using linear
interpolation between pointwise power estimates (dots) at fixed values of simulation configurations.
likely complementary to other ‘Omics measures, and thus the
proposed N1PAS strategy could become an additional tool to
bridge the gap between RNA-Seq data and clinical translation.
For example, one could investigate whether splicing events occur
in a coordinated way in response to a stimulus or perturbation
like a medication. A practical limitation is the relative rarity of
paired RNA-Seq data (compared to single-sample expression
data). It’s true that paired unaffected and cancer tissues are
currently uncommon. Yet novel experimental designs and
corresponding analyses will drive data collection protocols.
Indeed, as the National Institute of Health and National
Cancer Institute announced (Collins and Varmus, 2015),
there is interest in promoting and developing creative new
assays and analytics for predicting individualized disease
mechanisms and treatments. The N1PAS methods is a proof
of concept that demonstrates, with the blessing of high
dimensionality and integration of external knowledge, that signal
can aggregate within gene sets of paired samples and improve
their mechanistic interpretation.
To make clear of a potential clinical use of N1PAS within
the survival subtyping pipeline of Omics signals, imagine the
following scenario: a patient suffering from non-small cell
lung cancer consents to paired tumor-normal RNA-sequencing.
Patient-specific N1PAS odds ratios are first computed in the
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five survival-relevant pathways. Each survival-relevant pathway
has an associated odds ratio threshold (red dashed lines in
Figure 5). Based on this threshold, the patient is stratified into
either the Better or Worse survival groups. This informs on
both prognosis and on patient-specific disease mechanisms. Our
proposed method, however, only considers one pathway at a
time and therefore only partially explains survival, compared
to using all the odds ratios. Future studies could improve
survival prediction through aggregation of pathway metrics and
potentially have greater clinical utility in terms of prognosis in
addition to combining multiple ‘Omics measurements.
There are, of course, limitations and caveats to the methodo-
logy. The proportion clustering approach seeks to quantify
differential relative isoform usage and not differential gene
expression. However, a gene could be differentially expressed
based on the magnitudes of the sum across isoforms (typical
gene expression) as well as exhibit differential isoform usage.
As such, the signal obtained by N1PAS may not be purely
alternative splicing as traditional DEGs may still contribute.
Another issue is that different isoforms may not always be
indicative of differential protein structure or activity and
the biological impact may be minimal in these situations.
The model does not currently account for any noise that
may be present in RNA-Seq measurements, an important
consideration in the N-of-1 setting. Along those lines, the
estimated proportions pgA in Equation (1) depend on the initial
accuracy of the isoform abundances. This accuracy depends
on several aspects such as read depth, number of expressed
isoforms, and the specific method that has been used for
estimating the transcript abundance. Therefore, the estimated
proportions may have different variances and other statistical
properties. Our method does not explicitly account for these
differences. An important extension of our model could include
this uncertainty in estimating the proportions for a more holistic
and realistic formulation.
We acknowledge some limitations to the computational
experiments in the study. The significance of the survival
curves has been assessed on a single retrospective dataset
and could be over-optimistic. Future studies should include
prospective independent datasets. Our choice of pathway
database is outdated and more current databases may provide
more informed discoveries. One could imagine a variety
of alternative methods to form comparisons against N1PAS.
For example, p-value aggregation methods (such as Fisher’s
method) could be explored. Care must be taken, however,
as these methods often assume independent measurements.
Future studies could develop more sophisticated and novel
p-value aggregation approaches in this setting. Additionally, it
would be interesting to vary the pathway definitions across
several databases in future studies. Lastly, this proof of
concept study was designed to demonstrate the utility of
alternative splicing signals in absence of other signal to avoid
confounders. Therefore, in future studies, this method should
be opportunistically combined with any ‘Omics as well as
clinical signals in order to translate clinically useful predictions
with high accuracy.
CONCLUSION
We proposed a single-subject methodology, N-of-1-pathways
Alternatively Spliced, to quantify differential mRNA isoform
usage within biological pathways from paired-sample RNA-Seq
data. A target pathway validation study on paired normal-
tumor samples from TCGA reveals that in most data sets the
identified pathways generally concur with the annotated disease
(bladder cancer pathway was more likely to be enriched with
ASGs). More than just providing validation, this study also
highlights the vast patient-to-patient heterogeneity in alternative
splicing patterns. This heterogeneity actually motivates our N-of-
1 approach: despite having the same disease, patients vary greatly
in their splicing dysregulation. Our identification of subject-
specific splicing dysregulation offers targets for personalized
interventions and monitoring plans. Next, we applied our N1PAS
single-subject metrics to predict survival within a novel subtyping
pipeline. The output of this pipeline contains easy-to-interpret
diagnostics to enable precision medicine from transcriptome
data. Finally, we showed adequate statistical power and false-
positive rates in simulation studies.
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